Published in Cancer Sci on February 27, 2008
Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers. PLoS One (2011) 1.29
Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells. Haematologica (2009) 1.27
Expression of MAGE-C1/CT7 and MAGE-C2/CT10 predicts lymph node metastasis in melanoma patients. PLoS One (2011) 0.92
Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma. Cancer Immunol Immunother (2011) 0.91
Cancer/Testis Antigen MAGE-C1/CT7: new target for multiple myeloma therapy. Clin Dev Immunol (2012) 0.83
Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines. PLoS One (2011) 0.83
Chemotherapy enhances cross-presentation of nuclear tumor antigens. PLoS One (2014) 0.82
The CO-Regulation Database (CORD): a tool to identify coordinately expressed genes. PLoS One (2014) 0.80
The use of MAGE C1 and flow cytometry to determine the malignant cell type in multiple myeloma. PLoS One (2015) 0.76
Intratumoral Heterogeneity of MAGE-C1/CT7 and MAGE-C2/CT10 Expression in Mucosal Melanoma. Biomed Res Int (2015) 0.75
Immunotherapy in Multiple Myeloma Using Cancer-Testis Antigens. Iran J Cancer Prev (2015) 0.75
Centrosomal localisation of the cancer/testis (CT) antigens NY-ESO-1 and MAGE-C1 is regulated by proteasome activity in tumour cells. PLoS One (2013) 0.75
Expression of cancer/testis antigens MAGE-A, MAGE-C1, GAGE and CTAG1B in benign and malignant thyroid diseases. Oncol Lett (2017) 0.75
Cancer testis antigen MAGE C1 can be used to monitor levels of circulating malignant stem cells in the peripheral blood of multiple myeloma patients. J Cancer Res Clin Oncol (2016) 0.75
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 14.57
The genome of the social amoeba Dictyostelium discoideum. Nature (2005) 9.18
Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol (2000) 8.08
Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol (2000) 7.94
The DNA sequence and comparative analysis of human chromosome 20. Nature (2002) 7.40
Autoregulation and function of a repressor in bacteriophage lambda. Science (1976) 6.83
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet (1997) 6.83
How the lambda repressor and cro work. Cell (1980) 6.65
The Heidelberg classification of renal cell tumours. J Pathol (1997) 5.36
A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med (1998) 5.06
Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med (1998) 4.65
Recognition sequences of repressor and polymerase in the operators of bacteriophage lambda. Cell (1975) 4.28
Control elements in the DNA of bacteriophage lambda. Cold Spring Harb Symp Quant Biol (1974) 4.23
Gene regulation at the right operator (OR) of bacteriophage lambda. II. OR1, OR2, and OR3: their roles in mediating the effects of repressor and cro. J Mol Biol (1980) 4.02
Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol (2001) 3.83
Gene regulation at the right operator (OR) bacteriophage lambda. I. OR3 and autogenous negative control by repressor. J Mol Biol (1980) 3.64
Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res (1999) 3.41
Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. J Pathol (2001) 3.09
Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci U S A (2000) 3.00
Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst (2001) 2.93
Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst (1997) 2.92
Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol (2001) 2.91
Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res (1999) 2.79
Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci U S A (2000) 2.79
Long-term decline in lung function, utilisation of care and quality of life in modified GOLD stage 1 COPD. Thorax (2008) 2.71
Glutathione transferase null genotype, broccoli, and lower prevalence of colorectal adenomas. Cancer Epidemiol Biomarkers Prev (1998) 2.62
Bacteriophage-mediated generalized transduction in Escherichia coli and Salmonella typhimurium. Methods Enzymol (1991) 2.62
Sequence of Plasmodium falciparum chromosomes 1, 3-9 and 13. Nature (2002) 2.59
T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures. Proc Natl Acad Sci U S A (1984) 2.54
Genetic approaches to the analysis of microbial development. Annu Rev Genet (1982) 2.53
Production of stable cytolytic T-cell clones directed against autologous human melanoma. Int J Cancer (1987) 2.50
Functional interchangeability of DNA replication genes in Salmonella typhimurium and Escherichia coli demonstrated by a general complementation procedure. Genetics (1984) 2.42
Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events. Int J Cancer (1999) 2.26
Inferring tree models for oncogenesis from comparative genome hybridization data. J Comput Biol (1999) 2.25
Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol (2001) 2.20
Biliary adenocarcinoma. Characterisation of three new human tumor cell lines. J Hepatol (1985) 2.18
Promoters are in the operators in phage lambda. Nature (1974) 2.16
Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. J Exp Med (1989) 2.15
Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc Natl Acad Sci U S A (1998) 2.11
Sex-specific effect of body weight gain on systemic inflammation in subjects with COPD: results from the SAPALDIA cohort study 2. Eur Respir J (2009) 2.08
Simple phagemid-based system for generating allele replacements in Escherichia coli. J Bacteriol (1993) 2.06
Karyomegalic interstitial nephritis: further support for a distinct entity and evidence for a genetic defect. Am J Kidney Dis (1995) 2.01
Aspirin vs anticoagulation in carotid artery dissection: a study of 298 patients. Neurology (2009) 1.98
Primary B-cell gastric lymphoma: a clinicopathological study of 145 patients. Gastroenterology (1991) 1.94
Health hazards posed by feral pigeons. J Infect (2004) 1.93
Patterns of metastasis in muscle-invasive bladder cancer (pT2-4): An autopsy study on 367 patients. Urol Int (1999) 1.92
Antigens recognized by autologous antibody in patients with renal-cell carcinoma. Int J Cancer (1999) 1.91
Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer. J Clin Pathol (2001) 1.89
Characterization of two novel regulatory genes affecting Salmonella invasion gene expression. Mol Microbiol (2000) 1.88
Bremazocine: a potent, long-acting opiate kappa-agonist. Life Sci (1980) 1.87
Acetate and formate stress: opposite responses in the proteome of Escherichia coli. J Bacteriol (2001) 1.82
High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am J Pathol (2000) 1.82
Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. J Natl Cancer Inst (1999) 1.81
Path integration in mammals and its interaction with visual landmarks. J Exp Biol (1996) 1.80
Presence on a human melanoma of multiple antigens recognized by autologous CTL. Int J Cancer (1989) 1.80
Somatostatin receptors in human endocrine tumors. Cancer Res (1987) 1.77
Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res (1997) 1.76
Progressive diffuse leukoencephalopathy in patients with acquired immune deficiency syndrome (AIDS). Acta Neuropathol (1985) 1.76
Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. J Immunol (2000) 1.76
Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer (1996) 1.76
Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. Int J Cancer (1996) 1.75
Genome-wide association study of body mass index in 23 000 individuals with and without asthma. Clin Exp Allergy (2013) 1.74
Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer (1997) 1.72
Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. J Exp Med (2000) 1.67
Genetic transformation in freshwater: Escherichia coli is able to develop natural competence. Appl Environ Microbiol (1996) 1.65
High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer. Cancer Res (2001) 1.64
EB/RP gene family encodes tubulin binding proteins. Int J Cancer (1999) 1.63
Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines. Clin Cancer Res (2001) 1.62
Reaction mechanism of Escherichia coli dihydrodipicolinate synthase investigated by X-ray crystallography and NMR spectroscopy. Biochemistry (1997) 1.62
SSX: a multigene family with several members transcribed in normal testis and human cancer. Int J Cancer (1997) 1.60
Distance-based reconstruction of tree models for oncogenesis. J Comput Biol (2000) 1.55
Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer (2007) 1.52
Construction of evolutionary tree models for renal cell carcinoma from comparative genomic hybridization data. Cancer Res (2000) 1.45
Isolation and characterization of mutants with deletions in dnaQ, the gene for the editing subunit of DNA polymerase III in Salmonella typhimurium. J Bacteriol (1989) 1.45
Metastatic primitive neuroectodermal tumor of the kidney in adults. Eur Urol (2001) 1.44
Does acute occlusion of the carotid T invariably have a poor outcome? Neurology (2004) 1.44
Metastatic signet-ring cell melanoma in a patient with an unknown primary tumor. Histologic, immunohistochemical, and ultrastructural findings. J Am Acad Dermatol (1992) 1.43
Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: establishment of working models for human micrometastases. Cancer Res (1999) 1.43
GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics. Br J Cancer (2008) 1.41
Lung cancer in the Swiss HIV Cohort Study: role of smoking, immunodeficiency and pulmonary infection. Br J Cancer (2012) 1.41
Skin involvement in myelogenous leukemia: morphologic and immunophenotypic heterogeneity of skin infiltrates. Mod Pathol (1994) 1.40
TTF1 expression in non-small cell lung carcinoma: association with TTF1 gene amplification and improved survival. J Pathol (2009) 1.40
Inhibition of human melanoma cell growth in vitro by monoclonal anti-GD3-ganglioside antibody. Cancer Res (1984) 1.40
Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library. Cancer Res (2001) 1.39
Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer (1996) 1.39
An opioid benzodiazepine. Nature (1982) 1.39
Repetitive training of compensatory steps: a therapeutic approach for postural instability in Parkinson's disease. J Neurol Neurosurg Psychiatry (2004) 1.39
Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. Proc Natl Acad Sci U S A (2000) 1.36
Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma. Cancer Res (2001) 1.35
Patterns of chromosomal imbalances in advanced urinary bladder cancer detected by comparative genomic hybridization. Am J Pathol (1998) 1.34
holE, the gene coding for the theta subunit of DNA polymerase III of Escherichia coli: characterization of a holE mutant and comparison with a dnaQ (epsilon-subunit) mutant. J Bacteriol (1994) 1.31
Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochemistry (2001) 1.30
Development of malignant lymphoma in myoepithelial sialadenitis (Sjögren's syndrome). Virchows Arch A Pathol Anat Histol (1982) 1.30